Citi raised the firm’s price target on Neurocrine (NBIX) to $242 from $204 and keeps a Buy rating on the shares. The firm views the company’s Soleno (SLNO) acquisition as immediately accretive and says it fits well strategically. Citi upped Neurocrine’s target dafter adding Vykat to the model.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine Biosciences: Vykat XR Acquisition Unlocks Diversified Growth and Upside Potential Despite Near-Term Pipeline Lull
- Neurocrine price target raised to $220 from $192 at Oppenheimer
- Midday Fly By: Neurocrine to acquire Soleno, Oracle hires new CFO
- Neurocrine’s Soleno Acquisition: Accretive Rare-Disease Expansion Supporting Long-Term Growth and Buy Rating
- Morning Movers: Soleno pops, Neurocrine dips after acquisition agreement